{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:52:47Z","timestamp":1792878767642,"version":"4.5.0"},"reference-count":58,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T00:00:00Z","timestamp":1385942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Clozapine is underutilized in the management of treatment\u2010resistant schizophrenia. To understand contributing factors, we analyzed the frequency and causes of clozapine discontinuations that occurred over a 15\u2010year period in a clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Data were extracted from computerized records and from mandatory termination reports for discontinuation events 1993\u20132007. The reasons for termination were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over half of the patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a0183\/320; 57%) had at least one discontinuation (median time 609\u00a0days). The two most common causes for discontinuation were non\u2010adherence (35%) and side\u2010effects (28%). Hematological side\u2010effects accounted for 45% of all side\u2010effect associated discontinuations; most such patients remained eligible for clozapine treatment, and a significant fraction remained on clozapine after rechallenge. Central nervous system side\u2010effects accounted for 35% of side\u2010effect induced discontinuations. General factors significantly associated with discontinuation were African American race, older age at initiation of clozapine and less improvement in psychiatric symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In addition to anticipating and addressing causes of non\u2010adherence, psychiatrists should consider clozapine rechallenge in eligible patients and implement measures to mitigate clozapine\u2010associated sedation, seizures, and other side\u2010effects. Future studies should particularly address why African American and older patients may be more likely to discontinue clozapine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/acps.12233","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T05:16:53Z","timestamp":1386047813000},"page":"30-39","source":"Crossref","is-referenced-by-count":68,"title":["Discontinuation of clozapine: a 15\u2010year naturalistic retrospective study of 320 patients"],"prefix":"10.1111","volume":"130","author":[{"given":"M. C.","family":"Davis","sequence":"first","affiliation":[{"name":"VA VISN\u201022 Mental Illness Research Education, and Clinical Center Los Angeles CA 90073 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Psychiatry Service Louis Stokes Department of Veterans Affairs Medical Center Cleveland OH 44106 USA"},{"name":"Department of Psychiatry Case Western Reserve University Cleveland OH 44106 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Strauss","sequence":"additional","affiliation":[{"name":"Psychiatry Service Louis Stokes Department of Veterans Affairs Medical Center Cleveland OH 44106 USA"},{"name":"Department of Psychiatry Case Western Reserve University Cleveland OH 44106 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. E.","family":"Konicki","sequence":"additional","affiliation":[{"name":"Psychiatry Service Louis Stokes Department of Veterans Affairs Medical Center Cleveland OH 44106 USA"},{"name":"Department of Psychiatry Case Western Reserve University Cleveland OH 44106 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"Jaskiw","sequence":"additional","affiliation":[{"name":"Psychiatry Service Louis Stokes Department of Veterans Affairs Medical Center Cleveland OH 44106 USA"},{"name":"Department of Psychiatry Case Western Reserve University Cleveland OH 44106 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.01.014"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11r06927"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj067"},{"key":"e_1_2_9_6_1","first-page":"CD000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali A","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.105833"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.03.003"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.6.3.5"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp130"},{"issue":"1","key":"e_1_2_9_12_1","first-page":"1","article-title":"Second\u2010generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"e_1_2_9_13_1","first-page":"CD000966","article-title":"Newer atypical antipsychotic medication versus clozapine for schizophrenia","author":"Tuunainen A","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.4.731"},{"issue":"3","key":"e_1_2_9_15_1","first-page":"3","article-title":"Reducing clozapine\u2010related morbidity and mortality: 5\u00a0years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld G","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.6.576"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/23.4.637"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00131746-200511000-00003"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0801"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900026638"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0511"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834ab34c"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0911"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401239509149622"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199803000-00003"},{"key":"e_1_2_9_26_1","volume-title":"VHA Handbook 1160.02","author":"Clozapine Patient Management Protocol (CPMP)","year":"2008"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"e_1_2_9_28_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology \u2010 Revised (DHEW Publ No ADM 76\u2010338)","author":"Guy W","year":"1962"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.09.008"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0210"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.669"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2005.12.001"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_2_9_34_1","first-page":"CD008016","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"5","author":"Leucht S","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.4.519"},{"key":"e_1_2_9_37_1","first-page":"1663","article-title":"Use of clozapine in Texas state mental health facilities","volume":"50","author":"Rascati KL","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_9_38_1","unstructured":"National Center for Veterans Analysis and Statistics.Veteran Population.http:\/\/www.va.gov\/vetdata\/Veteran_Population.asp.United States Department of Veterans Affairs 2012."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C321"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007076"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.163.2.150"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01776.x"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0708"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.18.10.618"},{"key":"e_1_2_9_45_1","first-page":"133","article-title":"Clinical use of clozapine in a major urban setting: one year experience","volume":"20","author":"Chow EW","year":"1995","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0416"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0211"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.051979"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.27.6.211"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371202"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.1.20"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.12.1744"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820050009001"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60742-X"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01710.x"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033333"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12009"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214530"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12r08064"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facps.12233","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.12233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T19:58:22Z","timestamp":1695499102000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.12233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/acps.12233"],"URL":"https:\/\/doi.org\/10.1111\/acps.12233","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,2]]}}}